P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)

Shaji Kumar; Prashant Kapoor; Alvaro Alencar; Guru Subramanian Guru Murthy; Marc Hoffmann; John Pagel; Vishalkumar Patel; James Pauff; Pier Luigi Zinzani; Steven Le Gouill; Anthony R. Mato; Wojciech Jurczak; Lindsey E. Roeker

doi:10.1016/S2152-2650(22)00333-0

Back

P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)

Journal article

Peer reviewed

P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)

Shaji Kumar, Prashant Kapoor, Alvaro Alencar, Guru Subramanian Guru Murthy, Marc Hoffmann, John Pagel, Vishalkumar Patel, James Pauff, Pier Luigi Zinzani, Steven Le Gouill, …

Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S37-S38

2022-08

DOI: https://doi.org/10.1016/S2152-2650(22)00333-0

Appears in Miller School of Medicine - Latest Publications

Metrics

5 Record Views

Details

Title: P-003: A first-in-human phase 1 study of oral LOXO-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)
Creators: Shaji Kumar
Prashant Kapoor
Alvaro Alencar
Guru Subramanian Guru Murthy
Marc Hoffmann
John Pagel
Vishalkumar Patel
James Pauff
Pier Luigi Zinzani
Steven Le Gouill
Anthony R. Mato
Wojciech Jurczak
Lindsey E. Roeker
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.22, pp.S37-S38
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031786641202976